[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundacion Dexeus\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":171},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,67,94,118,146],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100646591","phase-4-embryo-quality-in-ovarian-stimulation-with-hmg-100646591",false,"NCT07691073","Embryo QUAlity in Ovarian Stimulation With hMG.","The Impact of Ovarian Stimulation With hMG on Embryo Quality in Advanced Age Women. A Randomized Controlled Trial","EQUAM","Inclusion Criteria:\n\n* Undergoing preimplantation genetic screening cycles\n* AMH 0.5 - 3.5 ng\u002Fml or AFC 5-20 (results of up to one year will be valid)\n* BMI 18.5 - 30 Kg\u002Fm2\n* Normal karyotypes in both partners\n\nExclusion Criteria:\n\n* Previous poor ovarian response (≤3 oocytes with a conventional stimulation protocol), according to Bologna criteria\n* Severe male factor requiring TESE (testicular sperm extraction)\n* Administration of any other drug potentially interfering with the treatment\n* Contraindication for hormonal treatment\n* Recent history of severe disease requiring regular treatment (clinically significant concurrent medical condition that could compromise subject safety or interfere with the trial assessment)\n* Monogenic disease to be detected with PGT-M\n* Biochemical and\u002For ultrasonographic evidence of polycystic ovarian syndrome\n* Endocrinological and\u002For autoimmune disorders","FEMALE","38 Years","41 Years",{"count":21,"type":22},240,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Ovarian stimulation (OS) is a key component of IVF, aimed at increasing oocyte yield and improving embryo development potential. While early protocols relied solely on FSH, newer approaches incorporate hMG and LH-based stimulation, allowing more individualized treatments for specific patient populations. Evidence suggests that hMG and recombinant FSH (rFSH) have comparable effectiveness in stimulation outcomes, and current guidelines support the use of both. However, the impact of different gonadotropins on embryo quality remains unclear, with mixed findings across protocols. Given the increasing use of combined rFSH and hMG and the limited data in PPOS protocols, this study proposes a randomized controlled trial to compare embryo quality between two different rFSH-hMG dosing strategies.",[28],"Infertility","NOT_YET_RECRUITING","2026-07-01",{"date":32,"type":33},"2026-07-08","ACTUAL",{"date":35,"type":22},"2026-09",{"date":37,"type":22},"2029-05",{"name":39,"class":40},"Fundacion Dexeus","OTHER",4,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100635739","ultra-rapid-blastocyst-vitrification-pilot-randomized-study-100635739","NCT07556601","Ultra-rapid Blastocyst Vitrification: Pilot Randomized Study","Clinical Validation of Ultra-rapid Blastocyst Vitrification: a Randomized Pilot Study in Oocyte Donation Cycles","Inclusion Criteria:\n\n* Recipients of donor oocytes\n* Blastocysts suitable for cryopreservation\n\nExclusion Criteria:\n\n* Cycles involving PGT\n* Cycles not reaching blastocyst stage.","18 Years","50 Years",{"count":52,"type":22},80,[54],"NA","Blastocyst vitrification is standard in assisted reproduction, but clinical data on ultra-rapid vitrification are limited. This pilot study evaluates the safety, feasibility, and preliminary clinical performance of an ultra-rapid blastocyst vitrification protocol compared with the standard approach.",[28],"RECRUITING","2026-06-29",{"date":60,"type":33},"2026-06-30",{"date":62,"type":33},"2026-06-01",{"date":64,"type":22},"2028-03",{"name":39,"class":40},2,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100574795","phase-4-intranasal-nafarelin-for-triggering-oocyte-maturation-100574795","NCT06763926","Intranasal Nafarelin For Triggering Oocyte Maturation","Intranasal Nafarelin Compared to Subcutaneous Triptorelin for Triggering Final Oocyte Maturation in Ovarian Stimulation: a Non-inferiority Randomised Controlled Clinical Trial","INFORM","Inclusion Criteria:\n\n* Women undergoing fertility preservation cycles with oocyte cryopreservation\n* Undergoing a progesterone-primed ovarian stimulation cycle (PPOS) with any commercially available gonadotropin preparation(s)\n* BMI 18 - 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to either of the study drugs\n* Hypopituitarism\n* Known pituitary tumour\n* Contraindication to intranasal medication administration\n* Previous poor response to agonist trigger","40 Years",{"count":77,"type":22},154,[25],"This is a non-inferiority randomised, controlled clinical trial comparing subcutaneous triptorelin to intranasal nafarelin for the final maturation of oocytes in women undergoing fertility preservation cycles with oocyte cryopreservation undergoing ovarian stimulation.",[81],"Fertility Preservation",[83,84],"IVF","GnRH agonist","2026-06-02",{"date":87,"type":33},"2026-06-04",{"date":89,"type":22},"2026-06-15",{"date":91,"type":22},"2028-01-15",{"name":39,"class":40},5,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":93},"100632548","ai-top-study-artificial-intelligence-for-trigger-optimization-100632548","NCT07515118","AI-TOP Study Artificial Intelligence for Trigger Optimization.","An Artificial Intelligence Based Approach for Selecting the Optimal Day for Triggering.","AI-TOP","Inclusion Criteria:\n\n* Undergoing COS for IVF with autologous oocytes, oocyte donation and elective fertility preservation with all monitoring USS (ultrasound scan) conducted at our centers.\n\nExclusion Criteria:\n\n* Medically indicated fertility preservation\n* Inability to attend clinic visits for monitoring.","42 Years",{"count":104,"type":22},644,[54],"To evaluate, in a randomized controlled trial, whether AI-guided monitoring and ovulation triggering leads to clinical outcomes comparable to those achieved through physician-led decision-making in patients undergoing ovarian stimulation for IVF.",[28,108,109],"Ovarian Stimulation","Artificial Intelligence","2026-04-21",{"date":112,"type":33},"2026-04-22",{"date":114,"type":33},"2026-04-08",{"date":116,"type":22},"2027-09",{"name":39,"class":40},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},"100583442","intraoperative-ultrasound-in-bowel-deep-endometriosis-100583442","NCT06876376","Intraoperative Ultrasound in Bowel Deep Endometriosis","Intraoperative Transvaginal and Endorectal Ultrasound for the Assessment of Bowel Deep Infiltrating Endometriosis","Inclusion Criteria:\n\n* Preoperative sonographic and\u002For MRI findings suggestive of bowel DIE (uterosacral ligaments, posterior vaginal wall, parametrium, retrocervical area, rectovaginal septum, rectum, and\u002For sigmoid colon).\n* Scheduled for surgical treatment (laparoscopy or robot-assisted laparoscopy).\n* Planned postoperative follow-up for at least 12 months.\n* Written informed consent provided before surgery.\n\nExclusion Criteria:\n\n* Planned surgery for diagnostic purposes only.\n* Pregnancy at the time of enrollment.\n* Poor understanding of Spanish or English.",{"count":126,"type":22},200,"OBSERVATIONAL","This study investigates the use of intraoperative transvaginal (IOTVUS) and\u002For endorectal ultrasound (IOERUS) in the surgical treatment of bowel deep infiltrating endometriosis (DIE).",[130],"Deep Infiltrating Endometriosis With or Without Bowel Involvement",[132,133,134,135,136],"Endometriosis","Intraoperative Ultrasound","Ultrasound","surgery","minimally invasive surgery","2026-03-25",{"date":139,"type":33},"2026-03-30",{"date":141,"type":33},"2025-01-20",{"date":143,"type":22},"2027-06",{"name":39,"class":40},1,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":18,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":156,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":168,"leadSponsor":170,"locationsCount":93},"100611588","phase-4-effect-of-semaglutide-on-embryo-quality-in-overweight-and-obese-patients-undergoing-in-vitro-fertilization-100611588","NCT07242534","Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.","Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. A Randomized Controlled Trial","SEQ","Inclusion Criteria:\n\n* ≤ 38 years\n* AMH \\>= 1 ng\u002FmL or AFC \\>= 6\n* Body mass index (BMI) between 27 kg\u002Fm2 and 40 kg\u002Fm2\n* Scheduled for IVF with freeze-all strategy\n\nExclusion Criteria:\n\n* Severe male factor (sperm concentration \\\u003C5M\u002FmL)\n* Type 2 diabetes mellitus\n* Prior use of GLP-1 Ras within the past year\n* Uncontrolled thyroid disorders\n* Contraindications to IVF or semaglutide treatment\n* Patients with chronic inflammatory diseases\n* Family history of hereditary or chromosomal diseases\n* Use of glucocorticoids or immunosuppressants\n* PGT-A\n* Use of medications affecting metabolism or inflammation",{"count":155,"type":22},62,[25],"This is a randomized, controlled clinical trial with a two-sided superiority hypothesis. The study evaluates whether a 12-week pre-treatment with semaglutide prior to ovarian stimulation improves the number of good-quality blastocysts in overweight and obese women undergoing in vitro fertilization (IVF), compared to no pre-treatment.",[28,159],"Obesity",[159,161,162,83,163],"Overweight","GLP-1 receptor agonist","ART","2026-01-19",{"date":166,"type":33},"2026-01-21",{"date":164,"type":33},{"date":169,"type":22},"2027-05",{"name":39,"class":40},""]